Literature DB >> 27020953

Crystal-induced arthritis after arthroplasty: 7 cases.

Salim Ahmed Yahia1, Valérie Zeller2, Nicole Desplaces3, Pascal Chazerain1, Luc Lhotellier4, Simon Marmor4, Jean-Marc Ziza5.   

Abstract

OBJECTIVES: To describe the occurrence in prosthetic joints of crystal-induced arthritis (CIA) defined as the deposition within the synovial membrane and/or joint cavity of calcium pyrophosphate dehydrate (CPPD) (chondrocalcinosis), sodium urate (gout), or hydroxyapatite.
METHODS: We retrospectively reviewed the 7 cases of prosthetic-joint CIA seen between 1993 and 2013 at a medical-surgical center specialized in the management of osteoarticular infections.
RESULTS: The 4 females and 3 males ranged in age from 67 to 79 years. Acute CIA occurred at the knee in 6 patients (5 with total knee arthroplasty and 1 with unicompartmental knee arthroplasty) and at the hip in 1 patient (with total hip arthroplasty). Time from arthroplasty to CIA varied from 7 days to 9 years. An abrupt onset was a consistent feature, with pain, complete loss of function, and local evidence of inflammation. A single patient had a fever and 6 patients had laboratory evidence of systemic inflammation. Joint aspiration showed hemarthrosis in 3 patients and inflammatory joint fluid with 20,000 to 79,000neutrophils/mm(3) in 6 patients. Joint fluid cultures were negative in 6 patients. CPPD crystals were evidenced in 5 patients, including 1 who also had hydroxyapatite crystals detected by electron microscopy after alizarin red staining. Monosodium urate crystals were found in 1 patient. The remaining patient had both CPPD crystals and positive cultures for Campylobacter fetus. In 5 patients, treatment with colchicine or a nonsteroidal antiinflammatory drug ensured prompt control of the symptoms and systemic inflammation. The patient with total hip arthroplasty underwent joint aspiration for hemarthrosis. In 1 patient, an intraarticular injection of triamcinolone hexacetonide improved the symptoms and systemic inflammation. The patient with Campylobacter fetus infection was treated with antibiotics, excision of the abscess, and synovectomy.
CONCLUSION: CIA may occur after arthroplasty, within synovial membrane remains or neosynovium developed around the prosthetic joint. CIA is a manifestation of a metabolic disease that persists and can reactivate after surgery. Routine testing for crystals is rarely performed in patients with sterile arthritis of a prosthetic joint, and crystals are difficult to detect in joints with hemarthrosis; consequently, the frequency of prosthetic-joint CIA may be underestimated. Although rare, CIA should be considered routinely when symptoms suggesting septic arthritis develop in a prosthetic joint, in order to avoid unnecessary prolonged antibiotic therapy and, in some cases, surgery. The treatment is usually simple.
Copyright © 2016 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Calcium pyrophosphate deposition disease; Chondrocalcinosis; Gout; Joint prosthesis; Prosthetic joint infection

Mesh:

Year:  2016        PMID: 27020953     DOI: 10.1016/j.jbspin.2016.01.006

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  10 in total

1.  Calcium pyrophosphate deposition disease after total knee arthroplasty: Comparison with periprosthetic joint infection.

Authors:  Kenyu Iwasaki; Tetsuro Nakamura; Satoshi Shin; Takeshi Nakagawa; Kei Itouda; Kuniyoshi Tsuchiya
Journal:  J Orthop       Date:  2019-02-27

2.  An 80-Year-Old Man With Fevers, Altered Mental Status, and Joint Effusions.

Authors:  Naomi Serling-Boyd; Zachary Wallace; Jana Jarolimova; Sheila Arvikar; Eli M Miloslavsky
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-03       Impact factor: 4.794

Review 3.  Therapy for CPPD: Options and Evidence.

Authors:  Mariano Andrés; Francisca Sivera; Eliseo Pascual
Journal:  Curr Rheumatol Rep       Date:  2018-04-19       Impact factor: 4.592

4.  Acute pseudogout presenting as an exception to Musculoskeletal Infection Society criteria in total knee arthroplasty: a case report.

Authors:  Julianne M Forlizzi; James M Ryan; Kristen E Galow; Aaron C Shang; Donald R Polakoff
Journal:  AME Case Rep       Date:  2020-07-30

5.  Palmatine Protects Against MSU-Induced Gouty Arthritis via Regulating the NF-κB/NLRP3 and Nrf2 Pathways.

Authors:  Juan-Juan Cheng; Xing-Dong Ma; Gao-Xiang Ai; Qiu-Xia Yu; Xiao-Ying Chen; Fang Yan; Yu-Cui Li; Jian-Hui Xie; Zi-Ren Su; Qing-Feng Xie
Journal:  Drug Des Devel Ther       Date:  2022-07-02       Impact factor: 4.319

6.  Moderating effects of immunosuppressive medications and risk factors for post-operative joint infection following total joint arthroplasty in patients with rheumatoid arthritis or osteoarthritis.

Authors:  Elizabeth Salt; Amanda T Wiggins; Mary Kay Rayens; Brent J Morris; David Mannino; Andrew Hoellein; Ryan P Donegan; Leslie J Crofford
Journal:  Semin Arthritis Rheum       Date:  2016-08-24       Impact factor: 5.532

7.  Calcium hydroxyapatite crystal deposition with intraosseous penetration involving the posterior aspect of the cervical spine: a previously unreported cause of neck pain.

Authors:  Julio Urrutia; Oscar Contreras
Journal:  Eur Spine J       Date:  2016-08-04       Impact factor: 3.134

8.  Early Onset Prosthetic Joint Infection and Bacteremia due to Campylobacter fetus Subspecies fetus.

Authors:  Igor Dumic; Mohan Sengodan; Joni J Franson; Diego Zea; Poornima Ramanan
Journal:  Case Rep Infect Dis       Date:  2017-08-08

9.  Gout After Total Knee Arthroplasty.

Authors:  Daniel J Chernoff; Jordan P Barker; Scott A Wingerter; Thomas L Shriwise
Journal:  Arthroplast Today       Date:  2020-04-08

10.  1-Palmitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol (PLAG) Mitigates Monosodium Urate (MSU)-Induced Acute Gouty Inflammation in BALB/c Mice.

Authors:  Su-Hyun Shin; Jinseon Jeong; Joo Heon Kim; Ki-Young Sohn; Sun Young Yoon; Jae Wha Kim
Journal:  Front Immunol       Date:  2020-04-24       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.